Basic Study
Intercellular mitochondrial transfer as a means of revitalizing injured glomerular endothelial cells

Tang LX et al. Cross-talk: Mitochondria transfer
Abstract

BACKGROUND
Recent discoveries have demonstrated that mesenchymal stem cells (MSCs) can rescue injured target cells via mitochondrial transfer. However, it has not been fully understood how bone marrow-derived MSCs can repair glomeruli in diabetic kidney disease (DKD).

AIM
To explore the mitochondrial transfer involved in MSCs rescue injured glomerular endothelial cells (GECs), both in vitro and in vivo.

METHODS

In vitro experiments were performed to investigate the effect of MSCs co-cultured with high glucose-induced GECs. The transfer of mitochondria was visualized using fluorescent microscopy. GECs were freshly sorted and ultimately tested for apoptosis, viability, real-time reverse transcriptase-polymerase chain reaction, western Blot, and mitochondrial function. Moreover, streptozotocin-induced DKD rats were infused with MSCs, and renal function and oxidative stress were detected by an automatic biochemical analyzer, and related-detection kit after two weeks. Kidney histology was analyzed by Hematoxylin and eosin, Periodic acid-Schiff, and immunohistochemical staining.

RESULTS
Fluorescence imaging confirmed that MSCs transferred mitochondria to injured GECs when co-cultured in vitro. We found that apoptosis, proliferation, and mitochondrial function of injured GECs were improved following co-culture. Additionally, MSCs decreased pro-inflammatory cytokines [interleukin (IL)-6, IL-1β, and tumor necrosis factor-α] and pro-apoptotic factors (caspase 3 and Bax). Mitochondrial transfer also enhanced the expression of superoxide dismutase 2, B cell lymphoma-2, glutathione
peroxidase (GPx) 3, and mitofusin 2 and inhibited reactive oxygen species (ROS) and dynamin-related protein 1 expressions. Furthermore, MSCs significantly ameliorated functional parameters (blood urea nitrogen and serum creatinine) and decreased the production of malondialdehyde, advanced glycation end products, and ROS, whereas they increased the levels of GPx and superoxide dismutase in vivo. In addition, significant reductions in the glomerular basement membrane and renal interstitial fibrosis were observed following MSCs treatment.

CONCLUSION
MSCs can rejuvenate damaged GECs via mitochondrial transfer. Additionally, MSCs improve renal function, and pathological changes in DKD may be related to the mechanism of mitochondrial transfer.

Key Words: Mitochondria transfer; Mesenchymal stem cells; Glomerular endothelial cells; Diabetic kidney disease; Mitochondrial dysfunction; Oxidative stress

Tang LX, Wei B, Jiang LY, Ying YY, Li K, Chen TX, Huang RF, Shi MJ, Xu H. Intercellular mitochondrial transfer as a means of revitalizing injured glomerular endothelial cells. World J Stem Cells 2022; In press

Core Tip: This study demonstrated that the MitoTracker Red CMXRos labeled mitochondria were transferred from mesenchymal stem cells (MSCs) to the high glucose-injured glomerular endothelial cells (GECs) in vitro. Additionally, GECs proliferation was enhanced, and GECs apoptosis was suppressed. Furthermore, in vivo experiments showed that MSC ameliorated renal function damage and pathological progress of diabetic kidney disease (DKD). These data suggest that MSCs may rescue damaged GECs and improve the renal function and pathological changes of DKD partly through mitochondrial transfer.
INTRODUCTION

The prevalence of diabetic kidney disease (DKD), also known as diabetic nephropathy, is increasing worldwide. The global all-age mortality rate from chronic kidney disease (CKD) increased 41.5% between 1990 and 2017[1]. Additionally, CKD caused the death of 1.2 million people in 2017 and resulted in an increase of 697.5 million cases of all-stage CKD[1]. Furthermore, a decomposition analysis showed that the burden of DKD accounted for about half the increase in CKD disability-adjusted life years[2]. Due to the high mortality rate, morbidity, and financial burden, DKD is an urgent public health issue.

Amongst the many known mechanisms of DKD pathophysiology, the mechanism of mitochondrial dysfunction appears to play an essential role in its development[3,4]. Mitochondria play vital roles in biological processes such as oxidative phosphorylation, cellular metabolism and cell death[5]. Recent studies indicate that mitochondrial damage occurs in glomerular endothelial cells (GECs) and podocytes in DKD[6,7]. Moreover, hyperglycemia results in mitochondrial dysfunction[8], which produces an excessive amount of reactive oxygen species (ROS), especially in GECs[6].

Mesenchymal stem cells (MSCs) have the potential to treat diabetes-related complications. However, their therapeutic effects and mechanisms of action haven’t been determined as of yet. Notably, a possible benefit of stem cells might be their ability to release mitochondria[9]. Transferring mitochondria from human bone marrow MSCs (BMSCs) to human umbilical cord vein endothelial cells (HUVECs) has been suggested to reduce apoptosis, stimulate proliferation, and restore transmembrane migration in injured HUVECs[10]. In streptozotocin (STZ)-induced diabetic animals, Konari reported the transfer of mitochondria from systemically administered BMSCs to renal proximal tubular epithelial cells (PTECs)[11]. Moreover, when BMSCs transferred their mitochondria to lung epithelial cells[12] and cardiomyocytes[13], it resulted in increased adenosine triphosphate (ATP) levels and apoptosis suppression. In addition, MSCs’ mitochondria can be transferred to myocardial cells[14], alveolar epithelial cells[15], and astrocytes[16], which restore cellular oxidative respiratory function and reduce
apoptosis. Therefore, a new concept for cell-cell signals involving intercellular mitochondrial transfer is now proposed[9]. Because the pathological changes in many tissues are related to the impairment of mitochondrial function, replacing dysfunctional mitochondria with healthy donor mitochondria has broad research applications[16]. Supplementing exogenous healthy mitochondria to replace damaged mitochondria can improve the bioenergetics of damaged cells, reverse excessive ROS production, and restore mitochondrial function[17]. However, experimental data on how stem cells influence injured GEC mitochondria is limited.

Previous studies have focused on glomerular hyper-filtration, oxidative stress, advanced glycation end products (AGEs), activation of intracellular signaling pathways, and epigenetic changes in the pathogenesis of DKD[2]. However, dysregulation of mitochondrial metabolism leads to the occurrence and progression of DKD[7,18]. The importance of MSCs in glomerular development is still highly debated, but one theory is that MSCs provide an environment conducive to glomerular development. Further investigation of the mechanisms of action of MSCs should be conducted, particularly those that involve the interaction between GECs and grafted MSCs. This study was designed to determine if MSCs could repair GECs with dysfunctional mitochondria by transferring their mitochondria. This research supports the idea that stem cell mitochondrial transfer can treat DKD or other diseases with mitochondrial dysfunction.

MATERIALS AND METHODS

Cell cultures and cell lines

BMSCs were isolated from Sprague-Dawley (SD) rats (4-6 wk old) using the adherence exclusion method following previously published protocols[19]. The isolated cells were resuspended in endothelial cell medium (ECM) (ScienCell, California, United States) containing 10% (v/v) fetal bovine serum (FBS) (ScienCell, California, United States), 1% (v/v) penicillin-streptomycin (P/S) (ScienCell, California, United States), and then incubated at 37 °C with 5% circulating CO₂. BMSCs (passages 2-4) were used in the
following experiments. GECs were purchased (ScienCell, California, United States) and cultured in ECM containing 10% FBS, 1% P/S, and 1% (v/v) endothelial cell growth supplement (ScienCell, California, United States). GECs (passages 2-3) were used in the following experiments.

BMSCs were identified by differentiation potential and fluorescence-activated cell sorting (FACS) to evaluate the cell surface markers. BMSCs could be differentiated into osteogenic, adipogenic, and chondrogenic phenotypes when incubated in an osteogenic-, adipogenic-, or chondrogenic-inducing medium (Cyagen, Suzhou, China) according to the manufacturer’s instructions. Osteogenic, adipogenic, and chondrogenic differentiation capacity of BMSCs were observed using Alizarin red staining, Oil red O staining, and Alcian Blue staining, respectively, and photographed under the light microscope (Olympus, Tokyo, Japan). The results are shown in Supplementary Figures 1A-C. The BMSCs were incubated with PE-conjugated CD45 polyclonal antibody (BD Biosciences, United States) and fluorescein isothiocyanate (FITC)-conjugated CD44 polyclonal antibody (BD Biosciences, United States). The BMSCs expressed the antigen CD44 but not CD45 (Supplementary Figure 1D).

**Cell label and co-culture model**

The mitochondria of GECs and BMSCs were labeled to detect mitochondrial transfer before co-cultivation. GEC cells (5 x 10^5 cells) were first incubated with 200 nmol/L MitoTracker Green (Beyotime, Shanghai, China) for 25 min at 37 °C under 5% CO₂, and then nuclei were stained with Hoechst 33342 (Beyotime, Shanghai, China). BMSCs (5 x 10^5 cells) were incubated with 200 nmol/L MitoTracker Red CMXRos (Beyotime, Shanghai, China) for 30 min. BMSCs were co-cultured with GECs in a 1:1 ratio and incubated at 37 °C under 5% CO₂. GECs were pre-cultured in ECM complete medium supplemented with high D-glucose (30 mmol/L, Sigma, United Kingdom) for 24 h to induce stress. Cells were randomly divided into four groups: (1) Normal control (NC) group: ECM complete medium containing D-glucose (5.5 mmol/L); (2) NC + MSC group; (3) High glucose (HG) group: D-glucose (30 mmol/L); and (4) HG + MSC group.
A fluorescence microscope (Olympus, Japan) was used to examine live cells after 48 h of co-culture. For further analysis, supernatants and cells were collected.

**Flow cytometry and sorting**
To examine the protective effects on the injured GECs, FACSaria III analysis (BD Biosciences) was used on at least $2 \times 10^7$ co-cultured cells after 48 h. GECs requiring sorting were pre-labeled with CellTracker™ Violet (CTV) (Invitrogen, United States). Sorting and purification were performed based on CTV-positive labeled cells. Following the cell sorting, GECs were tested for apoptosis, viability, ROS measurement, western blot, and mitochondrial function.

**Measurement of cell apoptosis and viability**
Annexin V-FITC/PI Apoptosis Detection Kit (Beyotime, Shanghai, China) was used to determine apoptosis after co-culturing for 48 h. The sorted GECs were resuspended in 195 µL Annexin-binding buffer according to the manufacturer’s instructions. In brief, approximately 5 µL of Annexin V-FITC working solution and 10 µL of PI were added to a $1 \times 10^5$ cell suspension in darkness over 20 min. The fluorescence intensity was analyzed by BD FACScielexa (BD Biosciences) within 1 h. Annexin V-FITC or PI staining results were calculated to indicate the early or late stages of apoptosis, respectively.

The cell viability was estimated using the Cell Counting Kit-8 (CCK-8) (Beyotime, Shanghai, China). GECs were plated in 10 µL of CCK-8 and incubated for 2 h in 96-well microplates filled with culture medium. The fluorescent microplate reader (FLx800™, BioTek, United States) was used to take readings at 450 nm, and a decrease in optical density was interpreted as a decrease in viability.

**Assessment of ATP production**
A luciferin-luciferase bioluminescence assay was used to assess ATP production. Briefly, the sorted GEC cells were collected, subjected to a single freeze-thaw cycle, and
centrifuged. To measure ATP levels, supernatants were collected using an ATP
determination kit (Invitrogen, United States), following instructions from the kit
manufacturer and the published protocol[20]. Standard curves normalized with protein
concentrations (nmol/L ATP/μg protein) were used to calculate the ATP concentration.

**Mitochondrial membrane potential**

Mitochondrial membrane potential (ΔΨm) was examined in live cells by the enhanced
mitochondrial membrane potential assay kit (JC-1) (Beyotime, Shanghai, China). Briefly,
6 × 10⁵ GEC cells were incubated with 0.5 mL JC-1 (1 ×) working solution in complete
culture medium for 30 min at 37 °C and centrifuged at 600 g for 3 min. Then, the cells
were resuspended with 1 mL JC-1 staining buffer. Carbonyl cyanide 3-
chlorophenylhydrazone (10 μmol/L; Beyotime, Shanghai, China) treated cells were
used as a positive control. The fluorescence intensity was analyzed by BD FACSCelesta
(BD Biosciences) for quantitative analysis.

**ROS and interleukin-6 measurement**

Intracellular ROS and mitochondrial ROS were measured using flow cytometry,
following cell staining with a DCF-DA probe (Beyotime, Shanghai, China) and
MitoSOX™ Red fluorescent probe (Invitrogen, United States), respectively. Freshly
sorted GEC cells were seeded in a 48-well plate at a concentration of 1 × 10⁴ cells per
well and then cultured in a growth medium for 12 h to completely adhere to the wall
surface. Cell pellets were collected after staining with DCF-DA (5 μmol/L) or
MitoSOX™ Red (5 μmol/L) for 30 min at 37 °C, and fluorescence was detected with a
flow cytometer. The level of interleukin (IL)-6 was measured according to the
manufacturer’s instructions for the enzyme-linked immunosorbent assay (ELISA) kit
(Invitrogen, United States).

**RNA extraction and real-time reverse transcriptase-polymerase chain reaction**
Real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) was used to detect caspase 3, B cell lymphoma (Bcl)-2, Bax, tumor necrosis factor (TNF)-α, and IL-1β mRNA expression levels. Briefly, total RNA was isolated from cells or kidney tissues using Trizol reagent (Beyotime, Shanghai, China). With the Applied BiosystemsTM 7500 RT-qPCR System (Thermo Fisher Scientific), RNA reverse transcription was performed with the SuperScript III (Invitrogen, United States), followed by RT-qPCR with SYBR Green master mix. GAPDH served as an internal control. All samples were analyzed in triplicate. RT-qPCR results were analyzed by the 2^\text{-\Delta\Delta Ct}\ method and then converted to fold changes. All primer sequences were obtained from publications and used in the synthesis (Servicebio, Wuhan, China), and the utilized sequences are shown in Supplementary Table 1.

**Western blot**

After extracting the proteins with RIPA buffer and protease inhibitor, the total protein contents were measured using a BCA assay kit (Servicebio, Wuhan, China). By normalizing protein content, all samples had the same quality and volume for further analysis. A wet-transfer method was used to separate proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis at 10% or 12% and transferred to nitrocellulose membranes. Polyvinylidene fluoride membranes were blocked in pure methanol before use and then blocked in 1 × TBS containing 3% bovine serum albumin (Solarbio, Beijing, China). Membranes were incubated overnight with primary antibodies: Anti-Bax (GB11690, Servicebio, Wuhan, China), anti-Bcl-2; ab196495, Abcam), anti-caspase-3 (GB11767C, Servicebio, China), anti-superoxide dismutase 2 (SOD2) (GB111875, Servicebio, China), anti-glutathione peroxidase 3 (GPx-3) (ab256470, Abcam), anti-dynamin-related protein 1 (DRP1) (8570S, CST), anti-mitofusin 2 (MFN2) (ab124773, Abcam), and anti-β-Actin (GB15001, Servicebio, China) antibodies. After washing with TBS-T, they were incubated with appropriately diluted horseradish peroxidase (HRP) conjugated Goat Anti-Rabbit immunoglobulin (Ig)G (GB23303, Servicebio, China) or HRP conjugated Goat Anti-Mouse IgG (GB23301, Servicebio,
China) as the secondary antibody. Protein bands were visualized using the BeyoECL Moon chemiluminescence system (Beyotime, China).

*Animal study*

All animal methods were carried out following the National Institutes of Health Guidelines for the care and use of laboratory animals and were handled according to protocols approved by the Animal Experimental Ethical Committee of Southeast University (Nanjing, China). Eight-week-old male SD rats (Southeast University Laboratory Animal Centre) were obtained by a single intraperitoneal injection of 60 mg/kg of STZ (Sigma-Aldrich, United States) dissolved in 10 mmol/L citrate buffer (pH 4.5), as our previous published study[25]. To verify the establishment of the diabetes model, fasting blood glucose (FBG) levels of ≥ 16.7 mmol/L were measured 3 consecutive days after STZ administration for 3 d. The diabetic rats were provided with standard rat food for 4 wk. An excretion rate of > 30 mg of 24-h urinary albumin (U-Alb) was observed at week 4, suggesting a successful DKD[28].

DKD rats were randomly divided into 2 groups (n = 5). Group 1 was treated with 2 × 10^6 MSCs (pre-labeled with 200 nmol/L MitoTracker Red CMXRos) dissolved in 100 μL Hank’s Balanced Salt Solution (HBSS) (DKD + MSC group), and group 2 received HBSS (DKD group) by tail vein injection. Five non-diabetic rats served as a normal control group (NC group). Rats were sacrificed 2 wk after treatment for biochemical and histological analyses.

*Evaluation of FBG, 24 h U-Alb, serum blood urea nitrogen, serum creatinine, and AGEs levels*

The levels of FBG were measured before and after each STZ injection. Samples obtained from the tail vein were tested for FBG using a blood glucose meter (LifeScan, CA, United States). Metabolic cages were used to collect 24-h urine from mice. The levels of 24 h U-Alb, blood urea nitrogen (BUN), and serum creatinine (Scr) were conducted
using an AU2700 automatic biochemical analyzer (Olympus, Japan). AGEs levels were measured according to the ELISA kit’s instructions (Cusabio, China).

**Assessment of SOD, malondialdehyde, and GPx in kidney**

A homogenizer was used to homogenize approximately 100 mg of kidney tissue in 5% phosphate-buffered saline. After centrifugation, the clear supernatant was collected. SOD values were measured by the xanthine oxidase activity assay kit (Sigma-Aldrich, United States); the MDA level was measured by the thiobarbituric acid method (MDA colorimetric assay kit, Elabscience, China); and a colorimetric assay kit (Elabscience, China) was used to measure the GPx concentration, following the manufacturer’s protocol.

**Histological analysis**

Rat kidneys were dissected and fixed in 4% paraformaldehyde, embedded in paraffin, and 4 μm serial sections were then prepared for histological analysis under light microscopy or fluorescence microscope. TdT-mediated dUTP nick-end labeling (TUNEL) was done with an apoptosis detection kit (Servicebio, Wuhan, China) following the manufacturer’s instructions. Hematoxylin and eosin (HE) and Periodic acid-Schiff (PAS) staining were carried out under standard procedures, respectively. A random sample of three glomeruli from each rat was analyzed using image analysis software (Image-Pro plus 6.0) to determine its percentage of PAS-positive areas, expressed as a mesangial index. Immunohistochemical analyses were carried out using the rabbit anti-AGEs (1:300, bs-1158R, Bioss, Woburn, MA, United States) primary antibodies. HRP-conjugated goat anti-rabbit IgG (1:500, GB23303, Servicebio, Wuhan, China) was used to detect primary antibodies. The nuclei were subsequently stained with DAB, and three fields of view from each rat were digitized. The IOD from all fields was calculated using Image-Pro Plus 6.0.

**Statistical analysis**
Data are presented as the mean ± SD based on at least three independent experiments. The statistical analysis was conducted using IBM SPSS 26.0 (Chicago, IL, United States). Comparing multiple groups was done using a one-way analysis of variance, followed by Bonferroni’s post hoc test. The significance of the data was defined as $P < 0.05$.

**RESULTS**

*Transfer of mitochondria from MSCs to GECs can alleviate high glucose-induced GECs apoptosis and promote GECs proliferation*

As a visual demonstration of the mitochondria transfer, the mitochondria of the GECs and the BMSCs were labeled with MitoTracker Green and MitoTracker Red CMXRos, respectively, and the nuclei of GECs were labeled with Hoechst 33342 before cocultivation. CMXRos-labeled mitochondria rarely transfer from MSCs to NC-GECs. However, CMXRos-mitochondria of MSCs were markedly transferred into HG-induced damaged GECs *in vitro* (Figure 1A).

To further confirm that mitochondria transfer was involved in protecting GECs, RT-qPCR, CCK-8, western blot, and flow cytometry assays were performed. The mRNA (caspase 3, Bax) and protein (caspase 3, Bax) expression levels in the HG group were dramatically higher than those in the control group (Figures 1B and 1C). Interestingly, treatment with MSCs significantly inhibited this outcome (Figures 1B and 1C). The changes observed in the anti-apoptotic gene and protein Bcl-2 were opposite to those observed with Bax and caspase 3 (Figures 1B and 1C). The ratio of Bcl-2/Bax increased in the HG + MSC group compared to those in the HG group, although it was not statistically significant. Flow cytometry with Annexin V-FITC/PI staining and CCK-8 assay was used to detect cell apoptosis and viability, respectively. From these assessments, we observed that high glucose treatment significantly reduced the cell viability of cultured GECs and increased apoptosis (NC vs HG: 0.533 ± 0.053 vs 0.336 ± 0.043, $P < 0.001$). In contrast, MSCs co-culturing significantly reversed these outcomes (HG vs HG + MSC: 0.3358 ± 0.043 vs 0.439 ± 0.05, $P < 0.01$) (Figures 1D and 1E). These
results suggest that mitochondria transfer plays a notable role in the anti-apoptotic mechanisms of MSCs.

**Mitochondria transfer alleviated mitochondrial activity and oxidative stress in high glucose-induced GECs**

To evaluate the mitochondrial activity of GECs, *in vitro* co-culture experiments were performed. CTV-positive GECs were sorted by flow cytometry. Compared with the high glucose-induced GECs group, the ATP production of MSC-treated GECs was significantly upregulated ($5.59 \pm 0.58 \text{ vs } 6.91 \pm 0.84$, $P < 0.05$) (Figure 2A). Additionally, staining with the ΔΨm indicator, JC-1, revealed significant attenuation of GECs by flow cytometry at 48 h (HG vs HG + MSC: 69.21 ± 5.06 vs 80.44 ± 6.49, $P < 0.05$) (Figure 2B).

To determine the impact of the mitochondrial transfer on mitochondrial dynamics, protein levels of mitochondrial fission factor (DRP1) and fusion factor (MFN2) were analyzed. Representative western blots showed that treatment with MSCs decreased the levels of DRP1, whereas MFN2 levels had increased (Figure 2C). In addition, intracellular and mitochondrial ROS production was visualized using DCF-DA and MitoSOX Red ROS indicators, respectively. Compared with NC-GECs, high glucose significantly increased DCF-DA and MitoSOX Red fluorescent intensity, suggesting high levels of ROS. In contrast, pretreatment with MSCs attenuated HG-induced upregulation in ROS levels (Figure 2D). Moreover, expression levels of ROS-protective enzymes (SOD2 and GPx-3) increased after MSC treatment of HG-induced GECs (Figure 2E). We then analyzed the expression of inflammation cytokines in GECs cultured with or without MSCs to characterize the mechanism of mitochondrial transfer on HG-GECs. Expression of the TNF-α, IL-1β, and IL-6 inflammatory cytokines decreased significantly in the HG-GECs cultured with MSCs for 48 h. In contrast, the addition of MSCs did not affect the expression of inflammation cytokines in NC-GECs (Figures 2F and 2G). The above results demonstrate that direct co-culture with MSCs improved the capacity of GECs to resist oxidative stress.
**MSCs treatment improved renal function and relieved inflammation of DKD rat**

An animal model of STZ-induced DKD was established to explore the therapeutic effect of MSCs on DKD. Following MSC treatment for 2 wk, rats were sacrificed (5/5 in each group), and tissue specimens were collected for further analysis (Figure 3A). The FBG and 24 h U-Alb levels of the DKD and DKD + MSC groups were significantly higher than the NC group. There was no statistically significant increase in FBG or 24 h U-Alb in the MSCs group relative to the DKD group, although the levels showed a trend towards an increase (Figure 3B). A significantly higher serum BUN and Scr were found in the DKD group than in the control group, but MSC treatment significantly reduced these changes (Figure 3C). RT-qPCR was applied to evaluate the expression of apoptosis-related genes. Compared with the NC group, caspase 3 and Bax expression in DKD rats were significantly increased, suggesting increased pro-apoptotic mechanisms (Figure 3D). In contrast, MSC injection reduced the expression of the pro-apoptotic markers, caspase 3 and Bax. However, changes in the expression of the Bcl-2 anti-apoptotic were increased (Figure 3D). The ratio of Bcl-2/Bax increased in the DKD + MSC group compared to those in the DKD group, although the difference was not statistically significant. Levels of MDA (a marker of lipid peroxidation/oxidative stress) and AGEs (contribute to oxidative stress) were lower in the NC group than those in the other groups (Figure 3E). MSC significantly decreased AGEs and MDA compared to DKD rats (Figure 3E). Notably, each group’s GPx level (a marker of oxidative stress) were inversed (DKD vs DKD + MSC: 2.08 ± 0.29 vs 2.67 ± 0.2, P < 0.05) (Figure 3E). We then used DCF probes and the xanthine oxidase activity assay kit to evaluate the ROS generation and scavenging ability. ROS production decreased with the DKD group while SOD level increased after MSC administration (Figure 3F). Overall, these results suggest that MSCs can ameliorate the abnormal renal function of DKD rats.

**MSC treatment ameliorated renal pathological changes**

As shown in Figure 4, TUNEL, HE, PAS, and immunohistochemistry (IHC) staining (5/5 in each group) were performed on kidney tissue sections from selected
experimental groups. The TUNEL method was used to investigate the apoptotic cells of renal tissue. Figure 4A shows that the TUNEL-positive apoptotic cells in kidney tissue of DKD rats were increased, while positive expression decreased after injection of MSCs. In the DKD group, HE staining revealed an inflammatory cell infiltration in the renal tissue (Figure 4B). Additionally, PAS staining showed severe glomerular and tubular changes in the DKD group. Atrophied glomeruli, ectopic mesangial extracellular matrix, high glycogen levels, kidney interstitial fibrosis, and basement membrane thickening were also observed (Figure 4C). The DKD group showed a degenerative phenotype indicative of glomerular endothelial degeneration with HE and PAS staining, while MSC therapy alleviated these pathological changes (Figures 4B and 4C). Compared to the NC group, DKD and DKD + MSC groups showed significant increases in the mesangial index (58.69 ± 11.7 vs 195.13 ± 32.55, P < 0.001; 58.69 ± 11.7 vs 160.67 ± 29.12, P < 0.001; respectively) (Figure 4D). The mesangial indices in the DKD + MSC group were markedly lower than that of the DKD group (160.67 ± 29.12 vs 195.13 ± 32.55, P < 0.01). Figures 4E and 4F illustrate the kidney expression of AGEs as detected by IHC. A deficient level of immunofluorescence was observed around the renal corpuscle wall and the tubular basement membrane in the NC group. Interestingly, the DKD group showed higher expression of AGEs than the NC groups (64.53 ± 15.86 vs 8.58 ± 3.83, P < 0.001) or DKD + MSC group (64.53 ± 15.86 vs 52.62 ± 10.33, P < 0.05).

Notably, the DKD + MSC group showed significantly decreased immunofluorescence labeling around the capsule and on the tubular basement membrane.

**DISCUSSION**

Recently, the administration of BMSCs has been shown to accelerate kidney reconstitution[28,29]. However, the underlying mechanism of MSCs that promote DKD kidney reconstitution is not yet fully understood. Apoptosis of GECs induced by mitochondrial dysfunction is suggested to play a role in the development of DKD. Therefore, one potential mechanism in BMSC-mediated kidney reconstitution is via BMSC and GEC cell-cell communication, resulting in the rescue of the injured-GECs.
and promoting kidney reconstitution. MSCs can repair injuries in various ways, including secreting paracrine factors, transferring proteins and RNA, and transferring organelles such as mitochondria\textsuperscript{30}. In this study, we demonstrated a novel mechanism of MSCs in which they can transfer functional mitochondria into GECs in vitro. Therefore, the therapeutic effects of BMSC on DKD rats may be related to the mechanism of mitochondrial transfer.

From our investigations, fluorescent imaging revealed that CMXRos-labeled mitochondria were transferred extensively from MSCs to high glucose-induced stressed GECs. As previously reported, mitochondria of BMSCs could transfer to renal PTECs\textsuperscript{11} and HUVEC cells\textsuperscript{10}. Although recent studies have shown that mitochondrial transfer was bidirectional\textsuperscript{31-33}, our study did not find that the mitochondria of GECs were transferred to MSC, which may be due to the difference in the recipient cell species. Notably, our studies’ unidirectional transfer of mitochondria is consistent with previous investigations\textsuperscript{16,34-37} that demonstrated mitochondria transfer from MSCs to injured target cells.

Mitochondria are energy factories that control cellular survival, stress, and apoptosis\textsuperscript{38}. There has been evidence that MSCs can save damaged cells by transferring mitochondria, thus preventing tissue damage and regenerating metabolism\textsuperscript{5,10,12}. Co-culturing with MSCs improved ATP production and ΔΨm of injured-GECs. In addition, our results demonstrated that mitochondrial transfer from MSCs to GECs could reduce apoptosis and promote proliferation in HG-stressed GECs. The finding that mitochondrial transfer reversed target cell proliferation and apoptosis was supported by a previous study conducted by Feng et al\textsuperscript{10}, which showed that MSCs promoted HUVEC proliferation and reduced HUVEC apoptosis through mitochondria transfer from MSCs to injured HUVECs. Additionally, hyperglycemia causes excessive oxidative stress, which contributes significantly to the pathogenesis of diabetic complications\textsuperscript{5}. Apoptosis, ROS production, and defective mitophagy play crucial roles in DKD progression\textsuperscript{5}. An elevated level of ROS is a biomarker of mitochondrial dysfunction in diabetic kidneys\textsuperscript{5}. Fortunately, mitochondrial and intracellular ROS
generation was inhibited with MSCs supplementation, as well as the variation trend of SOD2 and GPx-3 levels. Furthermore, mitochondrial function was partially improved by MSC-mediated protection from *in vitro* investigations.

Recent studies indicate that mitochondrial dynamics (fusion and fission) play an essential role in mitochondrial distribution, maturation, and quality control[39]. In the DKD rat, fusion and fission of mitochondria are enhanced[40], similar to our findings that expression of DRP1 decreased and MFN2 increased. Mitochondria play a role in cellular stress-induced apoptosis through various molecular mechanisms. Essentially, mitochondrial toxicity triggers the release of pro-apoptotic factors, which activate latent forms of caspases, resulting in cell death[3]. Importantly, hyperglycemia causes oxidative stress, which initiates caspase activation, leading to the release of TNF-α and activation of the mitochondria-mediated apoptotic pathway[41]. Furthermore, pro-apoptotic factors (caspase 3 and Bax) and inflammation-related factors (IL-6, TNF-α, and IL-1β) were down-regulated. In contrast, anti-apoptotic factors (Bcl-2) were upregulated after HG-injured GECs were co-cultured with MSCs. Additionally, the ratio of Bcl-2/Bax increased in the HG + MSC group compared to those in the HG group. However, these differences were minor and did not reach statistical significance. Possible reasons for this might include the following: (1) A too large control (NC, NC + MSC) group could lead to non-statistically significant differences in HG, HG + MSC groups; and (2) We also had a small sample size, which may result in lower statistical power to detect differences between groups. These reasons may also be applicable to our *in vivo* experimentation and observations. In addition to their importance in intercellular mitochondrial transfer, these factors have also been associated with high glucose-related damage.

After MSC injection in the STZ-induced DKD rat model, there was no significant difference in the FBG level compared with the DKD group. These results agree with previous reports[4243], which may be related to the late treatment of MSCs and the missed opportunity to heal the acute pancreatic injury. Meanwhile, the level of 24 h U-Alb was not significantly different in the DKD + MSC group compared with the DKD
group. The reason may be due to the small sample or the short 2-wk duration of treatment. However, we did identify that the FBG and 24 h U-Alb levels in the DKD + MSC group were lower than those in the DKD group, although there was no statistical significance. Interestingly, a noteworthy finding was that BMSCs effectively repaired renal dysfunction (BUN and Scr), meanwhile observing a significant increase in GPx and SOD, indicating that MSCs can protect kidneys from DKD.

Increased AGEs in DKD is another critical contributing factor resulting in mitochondrial dysfunction and apoptosis of GECs\cite{43}. The main pathological change of DKD is glomerular lesions. A long-term and persistent high-glucose environment can activate protein kinase C and the renin-angiotensin system, induce accumulation of ROS and AGEs that damage endothelial cells, and generate proteinuria and glomerulosclerosis\cite{45}, which eventually aggravate renal function damage and progress of DKD. Furthermore, diabetics with glomerular damage may experience altered blood flow and oxygen delivery to other segments of the kidney\cite{3}. However, treatment with MSCs results in renal histological changes manifested by reductions in glomerular volume, inflammatory cell infiltration, glomerular basement membrane, and renal interstitial fibrosis, consistent with previously reported results\cite{42}. Therefore, MSCs can improve renal function and pathological changes in DKD to a certain extent.

Potential limitations of our study should be noted. First, further studies are warranted to explore and elucidate the mechanism of mitochondrial transfer from MSCs to injured-GECs. For example, Liu et al\cite{5} and Han et al\cite{13} reported that MSCs transfer mitochondria to injured target cells via tunneling nanotubes, and this might be of interest to elucidate the exact mechanism of mitochondrial transfer. In addition, BMSCs can also transfer their mitochondria to target cells via gap junction channels containing the connexin 43 protein\cite{12}, extracellular vesicles\cite{46}, or endocytosis\cite{47}. Second, since the laboratory conditions were unable to freeze renal tissue when they were obtained, the distribution of MSC mitochondria labeled with fluorescent in the tissue was not observed. Future studies are recommended to observe the map of MSC-derived mitochondria on DKD kidney tissue. Third, whether mitochondria transfer
from MSC to GEC directly affects the function of GEC needs further verification by blocking the mitochondrial transfer. Fourth, TUNEL detects the apoptosis of cells in the whole kidney tissue, but it could not distinguish the apoptosis of GECs. Therefore, multiple fluorescent markers may be used for added analyses. Fifth, we did not assess the percentage of GECs that were transferred with BMSC mitochondria. Our current objectives focus on how to promote mitochondrial transfer from BMSC to GECs and show these results in a future report. Sixth, a study has shown that with intravenous injection of MSCs, these cells do not reach the damage site but release exosomes that can[88]. The article also reported that neither infusion of MSCs induced significant fibrotic responses in organs (lungs, kidney, liver, and spleen), which might cause safety concerns. In our study, we did not assess the following issues: (1) The biodistribution of the BMSC and the ratio/number of BMSC were alive in a time course manner after the injection; (2) The safety of the BMSC injection; and (3) The level of liver injury (aspartate aminotransferase, alanine aminotransferase, and others). However, we are optimistic about being able to solve these problems in our ongoing research.

CONCLUSION
Our study provides insights into the mechanisms underlying MSCs’ ability to rescue injured GECs by a new cell-to-cell communication method of mitochondria transfer. Notably, mitochondria transfer alleviated mitochondrial damage and abated cellular apoptosis of GECs. Furthermore, the therapeutic effects of BMSC on DKD rats may be related to this mechanism of mitochondrial transfer.

ARTICLE HIGHLIGHTS
Research background
Mesenchymal stem cells (MSCs) can rescue injured target cells via mitochondrial transfer. However, little is known about how bone marrow-derived MSCs can repair glomeruli in diabetic kidney disease (DKD).
Research motivation
Mitochondria play vital roles in biological processes such as oxidative phosphorylation, cellular metabolism and cell death. Recent studies indicate that mitochondrial damage occurs in glomerular endothelial cells (GECs) in DKD and MSCs could transfer their mitochondria to target cells. However, the mechanism of how mitochondrial transfer contributes to the high glucose-injured GECs is not well-understood.

Research objectives
To investigate the mechanisms of mitochondrial transfer between MSC and high glucose-injured GECs or streptozotocin (STZ)-induced DKD rats. It will help us to better understand the rescue of MSCs on target cells or tissue.

Research methods
The mitochondria of GECs and MSCs were labeled before co-cultivation. A fluorescence microscope was used to examine the mitochondrial transfer, then cell proliferation and apoptosis were detected by western blot, real-time reverse transcriptase-polymerase chain reaction, Cell Counting Kit-8 and Annexin V-FITC/PI. The GECs mitochondria function [adenosine triphosphate (ATP), reactive oxygen species (ROS), mitochondrial membrane potential] were assessed by related-detection kit. A DKD rat was obtained by STZ-administration. Renal function and oxidative stress were detected by an automatic biochemical analyzer, and related-detection kit. In addition, histological were analyzed by Hematoxylin and eosin, Periodic acid-Schiff, and immunohistochemical.

Research results
Our results demonstrated that the MitoTracker Red CMXRos labeled mitochondria were transferred from MSCs to the high glucose-injured GECs, ATP levels were increased, and the membrane potential of mitochondria was stabilized. Additionally, the transfer of mitochondria decreased pro-inflammatory cytokines [interleukin (IL)-6, IL-1β, and tumor necrosis factor-α] and pro-apoptotic factors (caspase 3 and Bax).
Transfer of healthy MSC-derived mitochondria enhanced the expression of superoxide dismutase 2, B-cell lymphoma 2, glutathione peroxidase 3, and Mitofusin 2 and inhibited ROS (mitochondrial and intracellular) and dynamin-related protein 1 expression. Notably, a transfer of healthy mitochondria from MSCs suppressed GEC apoptosis and enhanced their proliferation. Furthermore, STZ-induced DKD animal experiments showed that MSC ameliorated renal function damage and pathological progress of DKD.

**Research conclusions**

Our data demonstrated the existing of mitochondrial transfer *in vitro*, which plays a pivotal role in the rescue of GECs. Moreover, MSCs repairs the renal function damage and pathological progress of DKD rats may be related to this mechanism of mitochondrial transfer.

**Research perspectives**

This study intended to reveal the role mechanism of mitochondrial transfer in the rescue of injured-GECs, which can provide a scientific basis for the potential therapeutic effects of MSCs on DKD.
| 1 | Lixia Tang, Ke Li, Yan Zhang, Huifang Li, Ankang Li, Yuancheng Xu, Bing Wei. "Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats", Scientific Reports, 2020 | 26 words — < 1% |
| 2 | Kaiming Liu, Liang Guo, Zhijian Zhou, Mengxiong Pan, Chuanzhu Yan. "Mesenchymal stem cells transfer mitochondria into cerebral microvasculature and promote recovery from ischemic stroke", Microvascular Research, 2019 | 24 words — < 1% |
| 3 | Ping Li, Mingjia Yang, Dong Hang, Yongyue Wei, Hongling Di, Hongbing Shen, Zhihong Liu. "Risk Assessment for Longitudinal Trajectories of Modifiable Lifestyle Factors on Chronic Kidney Disease Burden in China: A Population-based Study", Journal of Epidemiology, 2021 | 17 words — < 1% |
| 4 | Kuankuan Xiong, Lei Tan, Siliang Yi, Yingxin Wu, Yi Hu, Aibing Wang, Lingchen Yang. "Low-Concentration T-2 Toxin Attenuates Pseudorabies Virus Replication in Porcine Kidney 15 Cells", Toxins, 2022 | 14 words — < 1% |
|   | Author(s)                                                                 | Title                                                                 | Journal                                                                 | Year       | Crossref                        | Percentage |
|---|---------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|------------|---------------------------------|------------|
| 6 | Pascal Zhongping Wei, Cheuk Chun Szeto.                                  | "Mitochondrial dysfunction in diabetic kidney disease"               | Clinica Chimica Acta                                                   | 2019       | [Crossref](https://www.researchgate.net) | < 1%       |
| 7 | www.researchgate.net                                                      |                                                                     |                                                                       |            |                                 | < 1%       |
| 8 | Lei Fan, Can Liu, Xiuxing Chen, Lei Zheng et al.                         | "Exosomes - Loaded Electroconductive Hydrogel Synergistically Promotes Tissue Repair after Spinal Cord Injury via Immunoregulation and Enhancement of Myelinated Axon Growth" | Advanced Science                                                      | 2022       | [Crossref](https://www.dovepress.com) | < 1%       |
| 9 | [Www.dovepress.com](https://www.dovepress.com)                            |                                                                     |                                                                       |            |                                 | < 1%       |
| 10| assets.researchsquare.com                                                 |                                                                     |                                                                       |            |                                 | < 1%       |
| 11| [www.spandidos-publications.com](https://www.spandidos-publications.com) |                                                                     |                                                                       |            |                                 | < 1%       |
| 12| [ylbs.cbpt.cnki.net](https://ylbs.cbpt.cnki.net)                         |                                                                     |                                                                       |            |                                 | < 1%       |